Share information
258.70 €
-2.63 %
16/04/2026 17:35
-2.63 %
Open
High
Low
Volume
265.50 €
266.70 €
255.30 €
299,433
Latest News
15-Apr-2026
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
10-Apr-2026
Acquisition of own shares
03-Apr-2026
Acquisition of own shares
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)